StockWatch
·
Biotechnology: Biological Products (No Diagnostic Substances)
Quarterly ResultMay 20, 2026, 05:28 PM

Scilex Q1 Net Loss Widens to $45.65M; Revenue Up 72.1%

AI Summary

Scilex Holding Co. reported a significant increase in net loss for Q1 2026, reaching $45.65 million, compared to $26.08 million in Q1 2025. This widening loss occurred despite a 72.1% rise in net revenue to $8.61 million. The company also saw a shift to negative cash flow from operations and reported substantial unrealized losses on digital assets and equity method investments.

Key Highlights

  • Net revenue increased 72.1% to $8.61 million for Q1 2026, up from $5.00 million in Q1 2025.
  • Net loss widened to $45.65 million in Q1 2026, compared to $26.08 million in Q1 2025.
  • Loss per share was $(6.28) for Q1 2026, worsening from $(2.26) in Q1 2025.
  • Net cash used for operating activities was $(1.11) million in Q1 2026, a decrease from $6.01 million generated in Q1 2025.
  • Digital assets held totaled $65.35 million as of March 31, 2026.
  • Equity method investment decreased to $79.10 million as of March 31, 2026, from $159.40 million at December 31, 2025.
  • A reverse stock split of 1-for-35 was effected on April 15, 2025.
  • A note receivable of $19.20 million was recorded as of March 31, 2026.